PhysioWave Introduces PhysioWave Pro™ for Pulse Wave Velocity Measurement at the Annual American Heart Association Meeting
Monday, 13 November 2017 () Studies Indicate PWV Can Be a Significant Biomarker for Assessing Cardiovascular Risk, and is Important in Primary Prevention
ANAHEIM, Calif. (PRWEB) November 13, 2017
PhysioWave, Inc, a developer of cardiovascular risk assessment instruments, is introducing the company’s new PhysioWave Pro™ device at the annual American Heart Association meeting being held in Anaheim, CA, November 11 through 15, 2017. The new device is designed to provide a straightforward method for healthcare providers to measure Pulse Wave Velocity (PWV) quickly and easily during patient intake (during weighing) for routine physical examinations. PWV is a clinically validated biomarker for the detection of potential cardiovascular (CV) risk.
“Multiple studies over the past several years, including the Framingham study published in 2010, have identified the measurement of PWV as one of the key biomarkers in assessing CV risk,” said Judith Swain, MD, Chief Medical Officer of PhysioWave. “Until recently, measurement of this biomarker would require a dedicated room and technician at substantial expense. With the PhysioWave Pro™, it will soon be as simple as stepping on a weighing scale to capture this critical measurement and help guide the physician’s next course of action.”
PWV measures arterial stiffness, which can be a precursor to possible future cardiac events. Arterial stiffness relates to the material properties of the arterial wall which, according to a scientific statement from the American Heart Association published in Hypertension in 2015, has functional consequences for the artery because it affects how pressure, blood flow and arterial diameter change with each heartbeat. The statement also indicates arterial stiffness is a major determinant of vascular impedance, and can modulate the pressure/flow relationship.
“Such studies have led researchers to conclude that higher aortic stiffness assessed by PWV is associated with increased risk for a first cardiovascular event,” said Laurent Giovangrandi, PhD, Chief Technical Officer and co-founder of PhysioWave. “The PhysioWave Pro™ is meant to provide a first-line assessment which can be used in the office. Depending on the assessment results, the clinician will be able to make more informed decisions on additional testing or additional therapy, which can be as direct as simple lifestyle changes.”
The PhysioWave Pro™ is an arterial pulse sensing technology, that is designed to provide PWV measurements in less than a minute, without disrupting clinical workflow. The technology is covered by multiple patents, and PhysioWave executives are anticipating a decision on their 510(k) application by the FDA early next year.
PhysioWave was founded by a group of Stanford researchers who realized that one of the most meaningful measures of cardiovascular health, Pulse Wave Velocity (PWV), was not in widespread use because it was cumbersome to obtain. They invented a way to measure PWV quickly and easily, while a patient is being weighed, with no change to clinical workflow. Realizing the potential of this technology to identify individuals at high risk of cardiovascular disease, the company developed a clinical-use product, with a clinical-grade home version to follow. For further information, visit http://www.physiowave.com
# # #
Cautionary Disclaimer Statement
This news release contains forward-looking statements relating statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of PhysioWave. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release. and PhysioWave will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.